Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial,ESC Heart Failure

当前位置： X-MOL 学术 › Esc Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial
ESC Heart Failure ( IF 3.8 ) Pub Date : 2021-11-22 , DOI: 10.1002/ehf2.13705
Lars H Lund _{1,

2} , Gianluigi Savarese _{1,

2} , Ashwin Venkateshvaran _{1,

2} , Lina Benson ₁ , Anna Lundberg ₃ , Erwan Donal ₄ , Jean-Claude Daubert ₄ , Emmanuel Oger ₅ , Cecilia Linde ₁ , Camilla Hage _{1,

2}

Affiliation

In the heart failure (HF) with preserved ejection fraction (HFpEF) PARAGON-HF trial, sacubitril/valsartan vs. valsartan improved mortality/morbidity in patients with left ventricular ejection fraction (LVEF) below median (57%). We assessed eligibility for sacubitril/valsartan based on four scenarios.

中文翻译：

根据 PARAGON-HF 试验，射血分数保留的心力衰竭患者是否适合使用沙库巴曲/缬沙坦

在保留射血分数 (HFpEF) 的心力衰竭 (HF) PARAGON-HF 试验中，沙库巴曲/缬沙坦对比缬沙坦改善了左心室射血分数 (LVEF) 低于中位数 (57%) 的患者的死亡率/发病率。我们根据四种情况评估了沙库巴曲/缬沙坦的资格。

更新日期：2021-11-22

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>